Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in biomarker-positive advanced solid tumors (K-BASKET)
NCT03491345Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Aug 2017
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in solid tumor (advanced stage), sponsored by Yonsei University. Primary endpoint: Overall Response Rate at 6 weeks. Status: unknown.
02
Drugs
avelumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03491345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491345.